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Objective: Our aim was to assess cost-effectiveness of mindfulness-based cognitive therapy (MBCT)
compared with enhanced usual care (EUC) in treating patients with persistent medically unexplained
symptoms(MUS).
Methods: A full economic evaluation with a one year time horizon was performed from a societal perspective.
Costs were assessed by prospective cost diaries. Health-related Quality of Life was measured using SF-6D.
Outcomes were costs per Quality-Adjusted Life Year (QALY). Bootstrap simulations were performed to obtain
mean costs, QALY scores and incremental cost-effectiveness ratios (ICERs).
Results: MBCT participants (n=55) had lower hospital costs and higher mental health care costs than
patients who received EUC (n=41). Mean bootstrapped costs for MBCT were €6269, and €5617 for EUC
(95% uncertainty interval for difference: −€1576; €2955). QALYs were 0.674 for MBCT and 0.663 for EUC.
MBCT was on average more effective and more costly than EUC, resulting in an ICER of €56,637 per QALY
gained. At a willingness to pay of €80,000 per QALY, the probability that MBCT is cost-effective is 57%.
Conclusion: Total costs were not statistically signiﬁcantly different between MBCT and EUC. However, MBCT
seemed to cause a shift in the use of health care resources as mental health care costs were higher and
hospital care costs lower in the MBCT condition. Due to the higher drop-out in the EUC condition the
cost-effectiveness of MBCT might have been underestimated. The shift in health care use might lead to
more effective care for patients with persistent MUS. The longer-term impact of MBCT for patients with
persistent MUS needs to be further studied.© 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Medically unexplained symptoms (MUS) are commonly encoun-
tered across all healthcare settings. About one in ﬁve patients
presenting at the general practitioner (GP)'s ofﬁce has medically
unexplained symptoms [1,2]. Often, these symptoms resolve sponta-
neously. However, in 10–16% of primary care patients the symptoms
persist and result in functional impairment [1,3]. Frequent attendance
because of persistent medically unexplained symptoms is seen in
2.5% of primary care patients. This group mainly consists of women
with a lower socioeconomic status [4].
Societal costs associated with persistent MUS are substantial [5,6],
they mainly consist of health care costs and costs of lost productivity.
Health care costs of patients with persistent MUS are high due to highCommunity Care, internal code
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.
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vier OA license.consultation rates in both primary and secondary care [7,8] and due
to often unnecessary medical procedures with the potential for iatro-
genic harm [5,9,10]. In the United Kingdom the incremental annual
health care cost incurred by patients with MUS was estimated at ap-
proximately 10% of the total health care expenditure for the working‐
age population [11]. In the United States 16% of the total medical care
costs are attributable to the incremental costs of MUS [7]. In addition,
disabilities caused by MUS lead to diminished employment participa-
tion: patients with persistent MUS are more on sick leave and have
higher rates of unemployment [12].
Clearly, effective interventions for MUS are needed in order to di-
minish functional impairment and societal costs. Mindfulness-based
cognitive therapy (MBCT) is a promising treatment in the ﬁeld of
MUS as it appears to be effective [13] and provides us with a new
approach: MBCT stimulates acceptance of symptoms [14]. An eco-
nomic evaluation of MBCT for patients with somatization disorder
has been performed within a recent Danish trial. MBCT was compared
to a specialized treatment consisting of a two-hour individual consul-
tation by a psychiatrist [15]. Total health care costs did not differ
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pension had decreased signiﬁcantly more in the MBCT condition.
In a recently randomized controlled trial the effectiveness of MBCT
was compared to enhanced usual care (EUC) for frequently attending
patients with persistent MUS [13]. Both MBCT and EUC succeeded in
improving current health status and mental and physical functioning.
However, MBCT led to an earlier improvement of mental functioning,
especially with regard to vitality and social functioning. In the context
of health care budget constraints, an economic evaluation of this ef-
fect can inform decisions which health care services to offer to these
patients. Therefore, we performed a cost-effectiveness analysis com-
paring MBCT versus EUC for patients with persistent MUS.
Methods
Design of RCT
This study was embedded in a randomized controlled trial examin-
ing the effects of MBCT on frequently attending patients in primary care
with persistent MUS. 125 Patients were randomly allocated to either
MBCT (n=64) or EUC (n=61) [13]. All patients belonged to the 10%
most frequently attending patients of the participating GPs (n=19),
and they fulﬁlled the DSM-IV criteria of anundifferentiated somatoform
disorder, which means that they had at least one physical symptom
which was not (fully) explained by a physical disorder or by substance
abuse, lasted for at least 6 months, led to functional impairment and
could not be put down to another psychiatric disorder. All patients re-
ceived a psychiatric interview at the pre-randomization assessment
which included the Mini-International Neuropsychiatric Interview
(MINI) [16] and the section on somatoform disorders of the Structural
Clinical Interview for DSM IV axis I disorders (SCID-I) [17].
Primary outcomes were current health status and mental and
physical functioning (SF-36 PCS and MCS) [18]. Assessments took
place at baseline, end of treatment and 9-month follow-up by ﬁlling
out postal or online questionnaires. Patients randomized to the EUC
condition were requested to refrain from attending mindfulness
training during the study period and they had the possibility to par-
ticipate in the mindfulness training after completion of the study.
Interventions
Participants randomized to MBCT received eight 2.5-hour sessions
of MBCT from experienced mindfulness trainers. Both trainers had
participated in an intensive two-year teacher training course for
mindfulness teachers, had many years of ongoing meditation prac-
tice, and both trainers taught more than 30 MBCT or MBSR courses
to patients with psychiatric disorders and/or physical conditions.
Participants were instructed to practice at home 6 days a week for
approximately 45 min a day. To support home practice, patients re-
ceived a folder with information about the individual sessions, home-
work assignments and forms to keep a record of their practice,
together with CDs with guided meditations and movement exercises.
Group size varied between 7 and 14 participants. Our training proto-
col was based on the MBCT format for patients with recurrent depres-
sion [19]. We made minor adaptations to the MBCT training protocol
to make it more suitable for patients with physical symptoms. The
program consisted of formal meditation exercises such as the body
scan, sitting meditation, walking meditation and mindful movement.
Participants were encouraged to cultivate awareness of everyday ac-
tivities, such as eating or taking a shower. In line with the original
Mindfulness-Based Stress Reduction format [20], we incorporated a
silent day to give participants the opportunity to deepen their mind-
fulness practice [21].
Patients in the EUC condition received usual care provided by their
GP and other health care professionals. The term ‘enhanced usual
care’ was considered appropriate as all patients received a psychiatricinterview. The GP was explicitly informed about the psychiatric diag-
noses resulting from the interview [22].Main results RCT
In the randomized controlled trial, current health status and phys-
ical functioning did not signiﬁcantly differ between groups. However,
participants in the MBCT group reported a signiﬁcantly greater im-
provement in mental functioning at the end of treatment (adjusted
mean difference 3.9, 95%CI 0.24 to 7.6), in particular with regard to vi-
tality and social functioning. Within the MBCT group, almost half of
the secondary outcome measures had signiﬁcantly improved at end
of treatment, whereas in the EUC group none had.Assessments cost-effectiveness study
A face-to-face pre-randomization assessment was performed in
which we assessed socio-demographic and clinical characteristics,
the current employment status and medication use in the past
month. Further assessments were performed with online or postal
questionnaires at baseline, 3 months and 12 months after randomi-
zation. To assess health care use and employment participation we
used a prospective cost diary in which patients were asked to note
their health care use and their employment participation per calendar
day. Given a societal perspective, the prospective cost diaries covered
employment participation and health care use per day. The prospec-
tive diaries were mailed to the patients before the start of each
month during the whole year of the trial. Patients were requested
to send the diary back at the end of each month. If the patient did
not send in the diary in time, our research team made a phone call
to the patient. We kindly requested patients to keep ﬁlling out the
diaries. A ﬁnal follow-up assessment was made by telephone at
12 months after baseline in which we assessed again the current em-
ployment status and medication use in the past month. The number
of attended MBCT sessions was registered by the mindfulness trainer.Unit prices
We used Standardized Dutch unit prices [23]. When a standard-
ized unit price was not available, prices were based on tariffs. Medica-
tion costs were obtained from the Dutch ‘Pharmacotherapeutic
Compass’ (the most used drug reference in The Netherlands) [24].
Medication costs which were not retrieved from these resources
(e.g. vitamin pills), were derived from suppliers on the Internet. If
these medication costs varied, we used the lowest price.
Productivity costs (i.e. when patients are unable to perform paid
work) were calculated according to the Friction Cost (FC) method
[25], implying that the number of hours patients were absent from
their job is multiplied with the actual gross wage per hour. The
cause for absence is not taken into account. Absence could for exam-
ple be due to illness, being ﬁred or resigning from a job. In FC, produc-
tivity costs are only counted as long as it takes to replace someone.
The friction period is deﬁned as the time needed to restore the initial
production level. After this friction period, costs to society fall back to
zero. For FC, standardized FC tariffs as well as the friction period of
160 days were obtained from the Dutch Manual for Costing studies
[23]. The tariffs are calculated based on the average value added per
working person. FC was calculated according to the standards, imply-
ing that when a patient was continuously absent for more than
160 days, it was assumed that this patients' place in the production
process was ﬁlled again and productivity returned to its original
level. Therefore, after these 160 days had passed, productivity costs
were considered zero. Price indices were used to convert costs to
the 2010 price level.
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Effectiveness was expressed as Quality Adjusted Life Years (QALY).
A QALY is a measure of life expectancy, weighted by the health-
related quality of life (HRQoL) represented by utility scores.
HRQoLwasmeasuredwith the SF-6D [26]which is based on the SF-36
[18]. The SF-6D revised the SF-36 into a six-dimensional health state clas-
siﬁcations system. This classiﬁcation system allows the calculation of a
utility score, which is a component of the QALY. It contains 6 dimensions:
physical functioning, role participation (combined role-physical and
role-emotional), social functioning, pain, mental health and vitality [26].
Each dimension has four to six levels. The speciﬁc areas or activities con-
tributing to the SF-6D index include current ability to engage in both
moderate and vigorous activities and current ability to bathe and dress
oneself. From the SF-36 Health Survey data, individual respondents can
be classiﬁed on any of four to six levels of functioning or limitations, on
each of six domains. These SF-6D health states can be converted into util-
ity scores by assigning preference weights. The preference weights are
derived from valuations of a sample of 249 SF-6D health states using
the standard gamble in a representative sample of the UK population
and range from 0.29 to 1.00 [27], with 1 representing perfect health.
From these utility scores, Quality-Adjusted Life Years (QALYs) were de-
rived using the area under the curvemethod by using the SF-36measure-
ments at baseline, 3 months and 12 months after baseline [28].
Data analysis
Patients who had ﬁlled out six or more prospective diaries and
whose data on the SF-6D were available from all three assessments
were included in the analysis. Costs were divided by the total number
of daysﬁlled out in the diaries andmultiplied by 365 to reach an estima-
tion of the costs per year. We used the independent sample Mann–
Whitney U test to determine whether the costs differed between the
two conditions at a signiﬁcance level of p=0.05. Since cost data are
generally highly skewed, and not distributed normally, bootstrap simu-
lations with 1000 replications were performed [29,30] to estimate un-
certainty intervals around the mean costs. For the same reasons, QALY
scoreswere bootstrappedwith 1000 replications. The uncertainty inter-
val is represented by the 2.5th and 97.5th percentiles.
Results of Incremental Cost-Effectiveness Ratios (ICER) bootstraps
are presented in cost-effectiveness planes. Cost-effectiveness planes
show differences in costs on the vertical axis and differences in effect
on the horizontal axis. Bootstrapped cost-effectiveness pairs located in
the north-west quadrant indicate MBCT to be inferior to EUC (more
costly and less effective than EUC). Cost-effectiveness pairs located in
the south-east quadrant showMBCT to be dominant over EUC (more ef-
fective and less costly than EUC). With respect to the other two quad-
rants (higher costs for better effectiveness and lower costs for lower
effectiveness), the choice of an intervention depends on the threshold
value, i.e. what society is prepared to pay for an effectiveness gain, or
willing to accept as savings for effectiveness loss. In these cases, an
ICER is determined. An ICER is calculated by dividing the difference in
costs between the treatments by the difference in effectiveness be-
tween the treatments. An ICER represents the extra amount of money
that has to be invested or will be saved to gain or lose one extra unit
of effect. In our study, the unit of effect was a QALY. Cost-effectiveness
acceptability curves (CEACs) [31] were constructed. They represent
the probability that, given a certain threshold for the willingness to
pay for a QALY, the intervention is cost-effective.
Secondary analyses
Secondary analyses were performed to assess robustness of the
results.
1. An analysis with a healthcare perspective, meaning that only direct
healthcare costs, including costs of MBCT and medication use,were considered. For this analysis we excluded the productivity
losses from our analysis.
2. A per protocol analysis: analyzing only those patients who adhered
to the study protocol. In line with previous MBCT trials, an ade-
quate dose of MBCT (i.e. the treated “per protocol” cases) was de-
ﬁned as participation in at least four MBCT group sessions [19,32].
Data are presented from the societal perspective.
3. An analysis without extreme cost outliers due to physical disease.
Data are presented from the societal perspective.
The results of all three secondary analyses are represented in a
CEAC.Results
Patients
Although 125 patients participated in the randomized controlled trial, we obtained
data for the cost-effectiveness analysis of only 96 patients, 55 in the MBCT condition
and 41 in the EUC condition (Fig. 1). Filling out prospective monthly diaries was expe-
rienced as burdensome by many patients, for 15 patients this was the main reason to
stop ﬁlling out these diaries. Of the 29 patients who were excluded from the
cost-effectiveness analysis, twenty-seven patients ﬁlled out less than six monthly dia-
ries. Two patients did hand in the monthly diaries, but not the questionnaires. Patients
who withdrew or dropped-out (n=29) seemed more severely impaired in their daily
functioning at baseline. They were less often employed (41% v. 52%), had a lower level
of education (17% only attended primary education v. 9%) and these patients had a
depressive or anxiety disorder (48% v. 28%) more often than those included in the
cost-effectiveness analysis. We present the cost-effectiveness data of the 96 patients
for whom sufﬁcient data were available. Table 1 shows baseline characteristics of
these patients. There were no signiﬁcant differences in baseline characteristics be-
tween patients in the MBCT condition and patients in the EUC condition. Costs, QALY
results, and cost per QALY ratios are based on all 96 patients.Employment status
At baseline 53% in the MBCT condition had a paid job, and 51% in the control con-
dition. At the end of follow-up 44% in the MBCT condition and 51% in the control con-
dition had a paid job. Unemployment rates were 11% in the MBCT condition and 15% in
the control condition at baseline. The unemployment rates increased in both condi-
tions to 20%. The percentage of patients on disability pensions was 13% in the MBCT
condition and 12% in the EUC condition at baseline. The percentage of patients on dis-
ability pensions slightly increased in both conditions: at the end of follow-up disability
pensions were provided to 16% in the MBCT condition and to 15% in the control
condition.Costs
Bootstrapped societal costs over 1 year were €6269 for MBCT and €5617 for EUC
which is a non-signiﬁcant difference (Table 2). With respect to health care costs, treat-
ment costs (including costs of the attendedMBCT sessions and, if attended, the 6-hour si-
lence retreat) were €450 per person randomized to MBCT. Apart from the costs for the
MBCT training, patients in the MBCT condition had lower hospital care related costs
than the patients in the EUC condition (€636 versus €861, p=0.18)and higher mental
health care costs (€431 versus €224, p=0.98). The majority of patients (63%) did not
make use of mental health care. Mean costs of participants who did use mental health
care were €1185 in the MBCT condition and €574 in the EUC condition (p=0.29). In
both conditions about one in ﬁve patients made use of alternative healers. Mean costs
for all patients were €100 per patient in this study, which makes the mean costs per pa-
tient who used alternative healers approximately €500. Medication costs were higher in
the MBCT condition (€673 versus €386, p=0.27 Mann–Whitney test). This was partially
due to a single very high cost outlier in the MBCT condition who used antiretroviral HIV
medication and had annual medication costs of €9513. His medication costs accounted
for 60% of the difference between MBCT and EUC medication costs.Effectiveness
Table 3 presents mean societal costs and SF-6D utility scores. Baseline utility scores
were 0.632 (SD 0.11) for MBCT and 0.639 (SD 0.10) for EUC, (p=0.983) (Fig. 2). Utility
scores increased in both conditions; from 0.63 to 0.69 in MBCT patients, and from 0.64
to 0.68 in EUC patients, an improvement of 0.06 and 0.04, respectively. As a result, total
QALY's over the 1-year period were 0.674 for MBCT and 0.663 for EUC. The
bootstrapped difference in QALY's between MBCT and EUC of 0.012 (95% CI −0.019
to 0.041) was not statistically signiﬁcant.
CONSORT Flow Diagram 
Assessed for eligibility (n=153)
Allocated to MBCT (n=64)
Withdrawal (n=3)
difficulty with questionnaires (n=1), physical disease 
(n=1), work situation (n=1)
Lost to follow-up (n=6)
difficulty with questionnaires and monthly diaries 
(n=4), physical symptoms (n=1), family situation (n=1)
Allocated to usual care (n=61)
Withdrawal (n=5)
difficulty with questionnaires (n=2), disappointed with 
allocation (n=2), psychological symptoms (n=1)
Lost to follow up (n=15)
difficulty with questionnaires and monthly diaries 
(n=11), disappointed with allocation  (n=1), migration 





not meeting inclusion criteria (n=18)
no impairment due to symptoms (n=12), 
physical disease explained symptoms (n=5), 
psychosis in medical history (n=1)
declined to participate (n=10)
lack of time (n=5), not interested (n=3), 
practical reasons impede participation (n=1), 
withdrew and requested removal of all data
(n=1)
Cost-effectiveness analysis (n= 55) Cost-effectiveness analysis (n= 41)
Not adhering to protocol (n=8)
Did not start MBCT (n=4), attended less than four 
sessions MBCT (n=4)
Per protocol analysis (n=47)
Not adhering to protocol (n=1)
Attended MBCT (n=1)







Fig. 1. Patient enrollment.
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In comparison to the EUC condition, bootstrapped total societal costs were €652
higher and QALY's were 0.012 higher in the MBCT condition. The ICER based on the
QALY shows that for one QALY gained the costs are €56,637, as MBCT was more costly
and more effective than EUC (Table 3). The bootstrapped results (Fig. 3) show that 52%
of the cost-effectiveness pairs are in the north-east quadrant, where MBCT is more
costly and more effective. Twenty percent are located in the north-west quadrant,
which is the inferiority quadrant. The south-east quadrant, i.e. the dominance quad-
rant, contains 25% of the replications. And the ﬁnal 4% of the cost-effectiveness pairs
are in the south-west quadrant, where MBCT is less costly and less effective. The
CEAC (Fig. 4) indicates that the probability of MBCT being cost-effective increases
with an increasing threshold value. If society's maximum willingness to pay would
be €0 for a QALY gain, the probability of MBCT being cost effective is 28%. And at a
threshold of €40,000 this is 48%. Assuming that society's maximum willingness to
pay is €80,000 for a QALY gain [33] the probability that MBCT is cost-effective is 57%.
Secondary analyses
Health care perspective
Costs per QALY gained when regarded from the health care perspective did not sig-
niﬁcantly differ from the costs per QALY gained when regarded from the societal per-
spective (Table 3). In the MBCT condition bootstrapped costs were €756 higher andQALYs 0.011 higher than in the EUC condition. Leaving out productivity losses led to
an ICER of €66,450 per QALY gained. Analysis from the health care perspective resulted
in higher costs per gained QALY than analysis from the societal perspective (ICER of
€56,637 per QALY gained). Assuming that society's maximum willingness to pay is
€80,000 for a QALY gain [33] the probability that MBCT is cost-effective is 55%.
Per protocol analysis
In the MBCT condition 8 patients (of patients included in the cost-effectiveness
analysis) did not follow the protocol, they attended less than four sessions of MBCT.
In the EUC one patient did not follow the protocol, she attended MBCT during the
year of study. Therefore the per protocol analysis consists of 87 patients (MBCT n=
47, EUC n=40). In the MBCT condition bootstrapped costs were €562 higher and
QALYs 0.011 higher than in the EUC condition. With respect to costs per QALY, costs
dropped from €56,637 in the main analysis to €53,198 in the per protocol analysis. As-
suming that society's maximum willingness to pay is €80,000 for a QALY gain [33] the
probability that MBCT is cost-effective is 56%.
Analysis without extreme cost outliers due to physical disease
There was one extreme cost outlier, this was a patient in the MBCT condition. This
patient had exceptionally high medication costs due to antiretroviral drugs, which
were prescribed for HIV. Medication costs exceeded €9500 per year, whereas all
other patients had medication costs between €0 and €2600, with mean €453 and me-
dian €230. After exclusion of this patient cost data of 95 patients were analyzed using
Table 1
Baseline characteristics of 96 study participants.
MBCT (n=55) EUC (n=41) p-Valuea
Age in years (SD) 47.0 (11.3) 48.1 (12.3) 0.66b
Women 43 (80.3) 31 (67.9) 0.78
Civil class
Married 27 (49.1) 18 (43.9) 0.18
Single/unmarried 20 (36.4) 12 (29.3)
Divorced 8 (14.5) 8 (19.5)
Widowed 0 (0.0) 3 (7.3)
Education levelc
Low 14 (25.5) 17 (41.5) 0.20
Middle 26 (47.3) 13 (31.7)
High 15 (27.3) 11 (26.8)
Employment status
Labor 29 (52.7) 21 (51.2) 0.94
Sick leave 3 (5.5) 3 (7.3)
Disability pension 7 (12.7) 5 (12.2)
Unemployment beneﬁt 2 (3.6) 1 (2.4)
Social welfare 2 (3.6) 4 (9.8)
Elderly pension 7 (12.7) 5 (12.2)
Student 3 (5.5) 1 (2.4)
No income 2 (3.6) 1 (2.4)
a Based on Pearson chi-square test, if no other test is indicated.
b Based on independent samples t-test.
c Education level was classiﬁed as low (primary and lower secondary education), mid-
dle (upper secondary education) and high (higher vocational training and university).
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bootstrapped costs were €647 higher and QALY's 0.016 higher than in the EUC condi-
tion. With respect to costs per QALY, costs dropped to €41,167. Assuming that society's
maximum willingness to pay is €80,000 for a QALY gain [33] the probability that MBCT
is cost-effective is 62%.Discussion
General results
Total societal costs did not signiﬁcantly differ between treatments,
costs per patient were approximately €650 higher for MBCT than forTable 2
Total mean costs per cost item and bootstrapped mean costs for subtotals per patient for M
Cost Category % of patients in
EUC condition
Mean EUC costs per
person (n=55)
% of patients in
MBCT condition
Health care costs
MBCT B2% 16 C93%
Primary careD 91% 252 93%
Hospital careE 79% 861 66%
Paramedical careF 57% 497 55%
Mental health careG 38% 224 36%
Occupational health careH 14% 26 14%
Alternative healersI 19% 101 18%
MedicationJ 95% 386 95%
Subtotal 2363
Bootstrapped subtotal 2351
Costs of lost production
Absent from paid work 49% 3283 45%
Bootstrapped subtotal 3251
Total costs 5646
Bootstrapped total costs 5617
A Mann–Whitney test.
B One patient in the EUC condition deviated from the study protocol and received MBCT
C Four patients in the MBCT condition did not start MBCT.
D Costs consist of contact with general practitioner (GP), home visit by GP, telephone or e-m
E Costs consist of outpatient contact with medical specialist, day treatment, inpatient treatm
F Costs consist of physiotherapy, movement therapy, speech-therapy, occupational therapy,
G Costs consist of contact with psychologist, psychiatrist, psychotherapist, social psychiatric
H Costs consist of contact with occupational health physician, company physician.
I Costs consist of contact with homeopath, orthomanual therapist, acupuncturist, haptonom
J Costs consist of prescribed medication and over the counter medication.EUC in the 1-year follow-up. The costs of lost productivity did not sig-
niﬁcantly differ between groups. There were notable differences in
the distribution of health care resources. Patients in the MBCT condi-
tion used less hospital care and more mental health care than those in
the EUC condition. Mean medication costs were higher (p=0.27) in
the MBCT condition, however this was mainly caused by one extreme
cost-outlier. In addition, we had less patients in the EUC condition
(n=41) than in the MBCT condition (n=55), this was due to higher
drop-out in the EUC condition. Patients who dropped out seemed
more severely impaired, therefore our results might underestimate
the costs of the EUC condition.
Utility scores increased from 0.63 to 0.69 in MBCT patients, and
from 0.64 to 0.68 in EUC patients, an improvement of 0.06 and 0.04,
respectively. The minimally important difference for SF-6D utility
scores is considered to be 0.04 points [34]. So, in both conditions
there was a clinically relevant effect on HRQoL. QALY's based on the
1-year period were slightly higher for MBCT, resulting in an ICER in-
dicating a costing €56,637 for a QALY gain. In the per protocol analysis
the societal costs for a QALY gain were €53,198. There was one ex-
treme cost outlier due to the use of antiretroviral drugs for HIV in
the MBCT condition, leaving out the extreme outlier led to an ICER
of €41,167 per QALY gained.
To date, there is no consensus about a reasonable threshold value
for cost-effectiveness. Most studies with the explicit goal to deter-
mine a threshold resulted in values ranging from €10,000 to
€27,000 [35–37]. However, in practice, thresholds used for appraisal
of new interventions may be higher, around €40,000 [38] for the UK
and €80,000 for The Netherlands [33]. The CEACs (Fig. 4) show a
range of thresholds, varying from €0 to €150,000. In the present
study, when applying a €80,000 per QALY threshold, the chance
that MBCT was cost-effective within the year of study lies between
56% and 62%.
Comparison to literature
Another intervention for MUS, cognitive behavioral therapy (CBT),
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Results of main and secondary analysis (mean bootstrapped costs and QALY's in Euros).
MBCT EUC Differences ICER
Costs per year QALY's Costs per year QALY's Incremental costs Incremental QALY's Costs per QALY (n=96)
Societal perspective (n=96) 6269 0.674 5617 0.663 +652 0.012 56,637
Health care perspective (n=96) 3107 0.674 2351 0.663 +756 0.011 66,450
Per protocol analysis (n=87) 6249 0.670 5686 0.660 +562 0.011 53,198
Analysis without extreme cost outliers (n=95) 6263 0.679 5617 0.663 +647 0.016 41,167
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study showed non-signiﬁcant differences in total costs. Costs due to
lost productivity were slightly lower in the intervention group, but
this difference was not signiﬁcant. Although the study reports an in-
crease in mental health outcomes on the SF-36, no cost-effectiveness
analysis was reported. Therefore we cannot compare our cost effective-
ness analysis to their study.
Fjorback et al. performed an economic evaluation of MBCT for pa-
tients with a somatization disorder [15]. The study showed a stronger
decrease in hospital costs after MBCT. Mental health care costs were
signiﬁcantly higher in the MBCT condition, this was attributable to
the extra costs incurred by the intervention. This partially corre-
sponds with our results. We found a difference in the distribution of
health care use between patients who attended MBCT and those
who did not. During the year of study, there was a trend for patients
in theMBCT condition to have lower costs for hospital care and higher
costs for mental health care compared with patients in the control
condition. In our study, the higher mental health care costs were
not caused by the MBCT training itself, because these costs were
reported separately. It can be speculated that somatizing patients
who attend MBCT become more willing to seek help for psychological
problems. They might have reached a deeper understanding of the
nature of their problems, or at least a different view upon which
health care services could be helpful to them. It would be interesting
to examine whether the different distribution of health care use per-
sists over the following years. One could expect that mental health
care workers are better equipped to deal with patients with MUS
than the more physically oriented specialists in the hospital.
The cost-effectiveness of MBCT has also been studied for patients
with recurrent depressions, Kuyken et al. compared MBCT to treat-
ment with antidepressant medication [32]. Similar to our study, the
total costs of the MBCT were slightly higher than the costs in the
control condition. Exploration of costs over time revealed that MBCT







Fig. 2. Utility scoresmedication over the ﬁrst 12 months. MBCT for patients with recurrent
depression seems to be cost-effective. Given the assumption that
society's willingness to pay for MBCT is zero, the probability of MBCT
being more cost-effective than the control treatment, was 42% in the
study by Kuyken et al. The results are not fully comparable to our
study, because in the study by Kuyken et al. the outcome was preven-
tion of relapse, whereas our outcome was more comprehensive:
the increase of a full QALY. In our study the probability of MBCT being
more cost-effective than the control treatment, would be 28% (societal
perspective) at society's willingness to pay of zero. It is important to
realize that society is probably willing to pay for a gain in quality of life.
Strengths
This study has several strengths. We examined a group of patients
causing relevant excess costs for society [6]. For the measurement of
costs we used a broad perspective: we included in- and outpatient
care, medication costs and productivity losses due to sickness absence.
In addition,we did not solely focus on costs, but also on the effectiveness
of the intervention. Although several economic evaluations of interven-
tions have been performed (costminimization studies), studies examin-
ing the cost-effectiveness of interventions for medically unexplained
symptoms are scarce[6]. This is the ﬁrst full economic evaluation
presenting the cost-effectiveness ratios ofMBCT for patientswith persis-
tent MUS.
Limitations
A number of limitations should be addressed. Firstly, data upon
health care use and employment participation combined with effec-
tiveness data were available for only 96 patients out of 125 patients
who were randomized for the trial [13]. Filling out prospective
monthly diaries was experienced as very burdensome by many


















Fig. 3. Bootstrapped costs and effects for cost per QALY, showing 1000 bootstrap replications for incremental cost-effectiveness of MBCT compared toEUC from a societal perspective.
Costs are on the y-axis, and effects on the x-axis, so a replication in the north-east quadrant means that MBCT is more effective but also more costly than EUC for that replication.
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Patients who decided to stop ﬁlling out the monthly diaries were
less often employed and had higher rates of depressive or anxiety
disorders at baseline than those who continued. In the EUC condition
more participants (n=19) decided to stop ﬁlling out the monthly
diaries than in the MBCT condition (n=8). These patients might
have been disappointed because they had to wait a year before they
could receive mindfulness training. Another possible reason for
lower drop-out in the MBCT condition is that ‘a mindful attitude’ re-
duced the aversion towards ﬁlling in the monthly diary. The higher
drop-out in the EUC condition might have led to an underesti-
mation of health care costs, underestimation of productivity loss
and overestimation of HRQoL. Multiple imputation could be used to
increase the number of patients included in the analysis [40]. Howev-
er, the high number of missing values would probably lead to the es-
timates resulting from the multiple imputation tending towards
extreme (and even impossible) values. We therefore decided not to
use multiple imputation results in this paper. Due to the higher
drop-out in the EUC condition the total costs in the EUC condition
might be an underestimation of the true costs and the HRQol might


























Fig. 4. Cost-effectiveness acceptability curves for costs per QALY. The curves indicate the pro
value (x-axis) for a QALY.cost-effectiveness of MBCT and is therefore conservative toward the
strategy under evaluation, which is the recommended approach in
cost-effectiveness research.
Second, the time horizon of the analysis was 1 year. This was proba-
bly too short to capture the long-term effects of MBCT and EUC on soci-
etal costs.Within the health care usewe see a shift in theMBCT condition
from hospital care towards mental health care. It remains unknown
whether the health care use distribution continues to be different be-
tween patients with persistent MUS who participated in MBCT and
those who received EUC. The follow-up of 1 year might have been too
short tomeasure the total effects of on HRQoL. A qualitative longitudinal
interview study was performed alongside the randomized controlled
trial [41]. This study described howMBCT stimulated patients to change
their behavioral patterns. A year after participation in MBCT these
changes were ongoing in about half of the interviewed patients. One
might speculate that MBCT may show further cost savings and HRQoL
improvements after this timepoint. Also, the societal costs in the year be-
fore participation in the trialwould have provided us further information
about the cost-effectiveness of our intervention, unfortunately this was
not part of the study design. In future trials more long-term information




Analysis without cost outlier
bability (y-axis) of MBCT being cost-effective compared with EUC, given the threshold
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losses, we took into account only the productivity losses of patients
who had a paid job during the year of study and who were absent
from work. This may have underestimated the actual productivity
losses [42]. The reason for absence is not taken into account in this
method. It can be expected that the time to replace an employee is
shorter if the employee loses his or her job, than when he/she is absent
due to illness. In this study we have not examined the reason why
participants lost their job, however, in the MBCT condition we had
more participants losing their job, this may have overestimated the
productivity losses in the MBCT condition. Next to the FC method, the
Human Capital (HC) approach can be used to estimate productivity
losses. This approach estimates the value of all potentially lost produc-
tion, whereas the FC method attempts to quantify actual production
losses. The FC is therefore considered to be more realistic, and
recommended in theDutch guideline for costing research [23]. General-
ly, compared to the FCmethod, theHCmethod results in higher produc-
tivity losses [43]. As the productivity losses were very similar between
the groups in the present study, it is not expected that the use of
the HC method would have signiﬁcantly changed our results. Also, we
did not incorporate losses due to diminished efﬁciency at work
(presenteeism) and losses of unpaid work and domestic tasks. For
these costs it is to date unclear how they should be measured and
valued [23,42,44]. We also left out direct costs for the patients such as
travel expenses. For the societal perspective this has probably led to
an underestimation of costs in both conditions.
At last, the economic evaluation is limited to the comparison of
only two possible alternatives. Other alternatives, such as cognitive
behavioral therapy have not been considered. The use of a single
RCT as a vehicle for economic evaluation is often a non-sufﬁcient
basis for decision making, because decision-makers need to be in-
formed about costs and effects for the full range of alternative inter-
ventions [45]. In that respect, the present study has contributed
evidence to the broader case of cost-effectiveness of treatment for
MUS.
Implications
MBCT is a relatively cheap intervention for MUS because it is a
group intervention. Individual therapies are generally more expen-
sive due to therapist costs. Although total costs were higher in the
MBCT condition in the year of follow-up, the provided health care
might have been more efﬁcient in the MBCT condition as these pa-
tients had less hospital related costs and higher mental health care
costs. Patients might have learned that hospital care is probably not
the most effective care for their problems in the long term.
We have several recommendations for future studies. Careful atten-
tion should be given to the methods of measuring costs. We lost many
patients due to the difﬁculties which they experienced with ﬁlling out
the prospective cost-diaries. One could consider providing patients
with a reimbursement per returned diary. As this is the ﬁrst cost-
effectiveness study of MBCT for patients with persistent MUS, the
cost-effectiveness should be re-examined in studies that followpatients
for a longer period of time. MBCT can lead to behavioral change in the
long term, studies with only a short term scopemight lead to low levels
of implementation of MBCT due to the relatively small short term
effects. Therefore it is of great importance to examine the costs and
effects of MBCT over several years. Also, the cost-effectiveness of MBCT
should be compared with the cost-effectiveness of other interventions
for MUS, such as cognitive behavioral therapy.
Conclusions and recommendations
Our study shows thatMBCThad a clinically relevant effect on HRQoL
of patients with persistent MUS. Although it still remains uncertain
whether MBCT is cost-effective, it is encouraging that MBCT wasacceptable and effective for these patients with persistent MUS. Due
to the higher drop-out in the EUC condition the cost-effectiveness of
MBCT might have been underestimated. MBCT seemed to cause a shift
in the use of health care resources asmental health care use was higher
and hospital care lower in the MBCT condition. The shift in health care
use might lead to more effective care for patients with persistent
MUS. In future research different comparators such as cognitive behav-
ioral therapy should be added, and studies shouldmeasure costs and ef-
fects with a longer follow-up.
The trial is registered at Trialregister.nl, number NTR2222.
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